Literature DB >> 668637

Reversible inhibitory effect of the non-steroidal antiandrogen flutamide (SCH 13521) on spermatogenesis in mice.

M Vojtísková, M Polácková, V Viklický, M E Khoda.   

Abstract

The effects of a prolonged subcutaneous administration of SCH 13521 dissolved in 0.3% hydroxypropyl cellulose (2-8 weeks in daily doses of 0.2 or 1.0 mg amounting to an estimated equivalent of experimental and curative doses used by others in laboratory animals and men) were studied in males of the mouse inbred strain C57BL/6. Following the treatment, the activity of spermatogenesis (expressed as the mean number of seminiferous tubules containing mature sperm and epididymal sperm count) was inhibited while the testis weight was not reduced, obviously due to an absolute increase of the interstitial tissue which was a marked histological feature of the testes, particularly following the higher doses of SCH 13521. Lower doses and shorter-lasting administration of the compound seem to inhibit the activity more effectively because after a prolonged administration reparatory processes tend to be triggered via a stimulatory effect on the synthesis of testosterone in Leydig cells. The solvent alone, hydroxypropyl cellulose, had some inhibitory effect on spermatogenesis. The lymphoid system remained both morphologically and functionally unaffected by SCH 13521 unlike the steroidal antiandrogen cyproterone actetate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 668637

Source DB:  PubMed          Journal:  Endokrinologie        ISSN: 0013-7251


  2 in total

Review 1.  FDA-approved medications that impair human spermatogenesis.

Authors:  Jiayi Ding; Xuejun Shang; Zhanhu Zhang; Hua Jing; Jun Shao; Qianqian Fei; Elizabeth R Rayburn; Haibo Li
Journal:  Oncotarget       Date:  2017-02-07

2.  Flutamide treatment reveals a relationship between steroidogenic activity of Leydig cells and ultrastructure of their mitochondria.

Authors:  Malgorzata Brzoskwinia; Laura Pardyak; Alicja Kaminska; Wacław Tworzydlo; Anna Hejmej; Sylwia Marek; Szczepan M Bilinski; Barbara Bilinska
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.